tiprankstipranks
Advertisement
Advertisement
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
PremiumCompany AnnouncementsInflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
3M ago
InflaRx Files Q1 2026 Financials with SEC via Form 6-K
Premium
Company Announcements
InflaRx Files Q1 2026 Financials with SEC via Form 6-K
3M ago
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study
Premium
Company Announcements
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study
3M ago
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
PremiumCompany AnnouncementsInflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
3M ago
InflaRx announces new izicopan in vitro findings
Premium
The Fly
InflaRx announces new izicopan in vitro findings
3M ago
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
Premium
Company Announcements
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
4M ago
IFRX Earnings this Week: How Will it Perform?
PremiumPre-EarningsIFRX Earnings this Week: How Will it Perform?
4M ago
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
Premium
Company Announcements
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
6M ago
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
Premium
Ratings
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100